RHT
Director Trades
| Date | Director | Value |
|---|---|---|
| 8/4/25 | A. Brinkworth | $30,236 |
| 22/6/25 | S. Panton | $17,500 |
Company News
Resonance Health expands clinical trial operations with Sun Pharmaceutical agreement
Australian healthcare technology and services company Resonance Health (ASX: RHT) has secured an agreement with Sun Pharmaceutical Industries to operate as its local Australian sponsor. As sponsor, Resonance will provide clinical research organisation, trial site and imaging analysis services for the global pharmaceutical giant’s Australian clinical trial of a new drug compound. Resonance estimates it […]
Resonance Health to acquire TrialsWest in $8m deal, expands global clinical trial reach
Perth-based Resonance Health (ASX: RHT) has secured a deal to acquire private clinical trial site and research centre TrialsWest, representing a major step forward in its growth strategy. TrialsWest is one of Australia’s most experienced clinical research centres, partnering with some of the world’s leading pharmaceutical and biotechnology companies to help bring new medicines and […]
Resonance Health’s FerriSmart MRI iron detection technology to be marketed in US
Resonance Health’s (ASX: RHT) “gold standard” FerriSmart magnetic resonance imaging service will be marketed and sold in the United Stated via an agreement with Accumen subsidiary 3DR Laboratories. FerriSmart uses artificial intelligence to analyse MRI images and report on liver iron concentrations within seconds. According to Accumen, the technology enables practitioners to effectively and efficiently […]
Resonance Health bags commercialising opportunity after partnering with US research foundation
Resonance Health (ASX: RHT) has inked a non-exclusive license agreement with Wisconsin Alumni Research Foundation (WARF), enabling the Australian healthcare company to use patents for commercialising new and alternative methods for measuring proton density fat fraction (PDFF) from MRI images. By combining Resonance’s expertise in iron and fat measurements with the use of technologies covered […]
Resonance posts healthy quarterly performance, boosts cash at hand figures
Australian healthcare company Resonance Health (ASX: RHT) has posted positive financials for the December 2018 quarter demonstrating an upward trend in earnings since the previous corresponding period. Cash receipts from customers totalled $907,000 for the quarter, representing an increase of 38% on receipts received in December 2017. The figure also surpasses cash receipts received for […]
Resonance signs distribution agreement to sell FerriSmart in medical imaging virtual marketplace
Resonance Health (ASX: RHT) has entered into a distribution agreement with the US makers of the world’s first cloud-based radiology marketing platform to promote and sell its FerriSmart automated liver-iron concentration quantification tool. Under the terms of the agreement, US-based company EnvoyAI will retain the non-exclusive rights to market FerriSmart on its virtual EnvoyAI Exchange […]
Resonance Health obtains FDA clearance for FerriSmart, allows distribution in the United States
Australian healthcare company Resonance Health (ASX: RHT) has received 510(k) clearance from the US Food and Drug Administration (FDA) for FerriSmart, its ground-breaking artificial-intelligence capable machine learning solution for the quantification of liver iron concentration (LIC). The clearance allows Resonance to distribute FerriSmart and commercialise it across the US, which also furthers the company’s overarching mission […]
Resonance Health develops a machine learned AI prototype for emerging markets
Resonance Health (ASX:RHT) has developed a machine learned artificial intelligence (AI) prototype for a low-cost test to measure liver iron concentration (LIC). This development follows results from a recent study confirming the urgent need for an affordable solution for measuring LIC in developing nations; where a widely-available but unvalidated T2* technique is potentially endangering patients’ […]